Northern Trust’s Acurx Pharmaceuticals ACXP Stock Holding History

Northern Trust’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,914	Closed	-$42.1K	–	4397
2025 Q4	$42.1K	Buy	+16,914	New	+$81.1K	﹤0.01%	4314
2025 Q3	–	Sell	-1,364	Closed	-$13.9K	–	4425
2025 Q2	$13.9K	Hold	1,364	–	–	﹤0.01%	4365
2025 Q1	$10.6K	Hold	1,364	–	–	﹤0.01%	4383
2024 Q4	$22.2K	Hold	1,364	–	–	﹤0.01%	4366
2024 Q3	$51.8K	Hold	1,364	–	–	﹤0.01%	4199
2024 Q2	$61.4K	Buy	1,364 +506	+59%	+$22.2K	﹤0.01%	4175
2024 Q1	$42K	Hold	858	–	–	﹤0.01%	4252
2023 Q4	$65.7K	Buy	+858	New	+$64.8K	﹤0.01%	4187

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Northern Trust's ACXP Position: Q1 2026 in Review

Northern Trust sold out of Acurx Pharmaceuticals (ACXP) in Q1 2026, closing a stake of 16,914 shares — an estimated $42.1K sold.

Northern Trust first reported a position in ACXP in Q4 2023 and held it in 8 quarters. The position peaked at $65.7K in Q4 2023. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

Northern Trust reported no remaining Acurx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Northern Trust sold 16,914 Acurx Pharmaceuticals shares in Q1 2026, an estimated $42.1K.
Northern Trust first reported a position in Acurx Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Northern Trust's Acurx Pharmaceuticals position peaked at $65.7K in Q4 2023.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.